Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Only a small fraction enters your bloodstream, limiting its systemic antioxidant effect
Nadolsky KZ et al
A personalised treatment plan will be discussed at your initial consultation
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
Eagle H, Oyama VI, Levy M, Horton CL,Fleischman R
-1775582746855.png&w=384&q=75)
![Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90]](https://www.researchgate.net/publication/370926483/figure/fig4/AS:11431281185432337@1693619320519/Structures-of-a-GLP-1-b-GIP-and-c-tirzepatide-19-88-90-Amino-acids-are.png)
